GSK and Sanofi Seek Regulatory Authorization for COVID-19 Vaccine

Sanofi (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) report intent to submit data from both their booster and Phase 3 efficacy trials as the basis for regulatory applications for a COVID-19 vaccine.  The Sanofi-GSK booster vaccine has provided a significant increase in neutralizing antibodies of 18- to 30-fold across vaccine platforms and age groups.  Thomas …

GSK and Sanofi Seek Regulatory Authorization for COVID-19 Vaccine Read More »